Ephedra Athletic Performance Claims Targeted In FDA Warning Letters
This article was originally published in The Tan Sheet
Executive Summary
Athletic performance claims for ephedrine alkaloid-containing dietary supplements should be discontinued unless they can be scientifically supported, FDA states in Feb. 28 warning letters to 26 marketers
You may also be interested in...
FDA Focusing On Ephedra Solution Within DSHEA Parameters, McClellan Says
FDA is committed to operating within the confines of the Dietary Supplement Health & Education Act rather than seeking changes in the law as it prepares for action on ephedra-containing dietary supplements, according to FDA Commissioner Mark McClellan, MD/PhD
FDA Focusing On Ephedra Solution Within DSHEA Parameters, McClellan Says
FDA is committed to operating within the confines of the Dietary Supplement Health & Education Act rather than seeking changes in the law as it prepares for action on ephedra-containing dietary supplements, according to FDA Commissioner Mark McClellan, MD/PhD
FDA Focusing On Ephedra Solution Within DSHEA Parameters, McClellan Says
FDA is committed to operating within the confines of the Dietary Supplement Health & Education Act rather than seeking changes in the law as it prepares for action on ephedra-containing dietary supplements, according to FDA Commissioner Mark McClellan, MD/PhD